Li Fan, Chen Jin-Hai, Liu Yang, Guan Guo-Xian, Lu Chuan-Hui
Department of Colorectal Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
The Third Clinical Medical College, Fujian Medical University, Fuzhou, China.
J Gastrointest Oncol. 2022 Apr;13(2):672-682. doi: 10.21037/jgo-22-269.
Whether all cT3 low rectal cancer patients should receive neoadjuvant chemoradiotherapy (nCRT) remains controversial. The depth of invasion beyond the muscularis propria of the cT3 rectal cancer is of great significance to the selection of a treatment plan and the evaluation of prognosis.
A retrospective analysis was conducted of 187 patients with stage cT3 low rectal cancer, who had been treated at the Department of Colorectal Surgery, The First Affiliated Hospital of Xiamen University from June 2010 to December 2012. The patients were divided into the nCRT group (88 cases) and no-nCRT group (99 cases). Possible significant prognostic factors [i.e., primary tumor volume (PTV), cell differentiation, circumferential resection margin (CRM), nCRT, age, sex, carcinoembryonic antigen (CEA), lymph node status, surgical procedure, etc.] were collected for estimation of disease-free survival (DFS), distant metastases rate (DM), local recurrence rate (LR). Independent predictive factors or survival were determined using Cox proportional hazards model.
The mean PTV was 16.2±11.1 (2.07-72.68) cm. In the univariate and multivariate analyses: nCRT hazards ratio (HR) =4.258, 95% confidence interval (CI): 1.912-9.483 (P<0.001); PTV HR =0.381, 95% CI: 0.181-0.804 (P=0.011); CRM HR =0.227, 95% CI: 0.097-0.532 (P=0.001). For the PTV ≤15 cm group, there were no significant differences between the nCRT and no-nCRT group in 3-year follow-up (P>0.05). For the PTV >15 cm group, there were significant differences between the nCRT and no-nCRT group in 3-year DFS (84.2% 51.1%; P=0.001), DM (13.1% 31.2%; P=0.017) and LR (2.9% 26.6%; P=0.009). For the CRM negative group, there were significant differences between the nCRT and no-nCRT group in 3-year DFS (94.0% 79.0%; P=0.008), LR (1.5% 10.7%; P=0.028) and DM (4.5% 13.5%; P=0.039).
For stage cT3 low rectal cancer patients, nCRT, PTV, and CRM were independent prognostic factors. NCRT may improve the survival of PTV >15 cm patients, but may not have a significant effect on patient with PTV ≤15 cm and CRM negative. Direct surgery is recommended for this group of patients.
所有cT3期低位直肠癌患者是否均应接受新辅助放化疗(nCRT)仍存在争议。cT3期直肠癌侵犯至固有肌层以外的深度对于治疗方案的选择及预后评估具有重要意义。
对2010年6月至2012年12月在厦门大学附属第一医院结直肠外科接受治疗的187例cT3期低位直肠癌患者进行回顾性分析。将患者分为nCRT组(88例)和非nCRT组(99例)。收集可能的重要预后因素[即原发肿瘤体积(PTV)、细胞分化程度、环周切缘(CRM)、nCRT、年龄、性别、癌胚抗原(CEA)、淋巴结状态、手术方式等],以评估无病生存期(DFS)、远处转移率(DM)、局部复发率(LR)。采用Cox比例风险模型确定生存的独立预测因素。
PTV均值为16.2±11.1(2.07 - 72.68)cm。单因素和多因素分析显示:nCRT风险比(HR)=4.258,95%置信区间(CI):1.912 - 9.483(P<0.001);PTV HR =0.381,95% CI:0.181 - 0.804(P=0.011);CRM HR =0.227,95% CI:0.097 - 0.532(P=0.001)。对于PTV≤15 cm组,nCRT组和非nCRT组在3年随访中无显著差异(P>0.05)。对于PTV>15 cm组,nCRT组和非nCRT组在3年DFS(84.2%对51.1%;P=0.001)、DM(13.1%对31.2%;P=0.017)和LR(2.9%对26.6%;P=0.009)方面存在显著差异。对于CRM阴性组,nCRT组和非nCRT组在3年DFS(94.0%对79.0%;P=0.008)、LR(1.5%对10.7%;P=0.028)和DM(4.5%对13.5%;P=0.039)方面存在显著差异。
对于cT3期低位直肠癌患者,nCRT、PTV和CRM是独立的预后因素。NCRT可能改善PTV>15 cm患者的生存,但对PTV≤15 cm且CRM阴性的患者可能无显著影响。建议该组患者直接手术。